Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts

Cancer Lett. 1996 Dec 20;110(1-2):149-54. doi: 10.1016/s0304-3835(96)04477-1.

Abstract

We studied the antiproliferative effect of recombinant human interferon-alpha/beta/gamma (rHuIFN-alpha/beta/gamma) and CPT-11 against human colon cancer xenografts in nude mice. CPT-11 (25 mg/kg) alone exhibited significant antiproliferative effects. Although rHuIFN-alpha/beta/gamma alone did not show antiproliferative activity, it markedly enhanced the antiproliferative activity of CPT-11. rHuIFN-alpha/beta/gamma significantly increased in the population of cells in the S-phase. rHuIFN-alpha/beta/gamma progressed cell cycle in the S-phase under the existence of CPT-11, which exhibited no effect on cell cycle progression. Because CPT-11 is known to exhibit antiproliferative effect on S-phase cells, IFNs, especially rHuIFN-alpha and beta, can enhance the antiproliferative effect of CPT-11 mediated by cell accumulation in the S-phase.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / pharmacology
  • Cell Division / drug effects
  • Colonic Neoplasms / drug therapy*
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • Humans
  • Interferon-alpha / pharmacology*
  • Interferon-beta / pharmacology*
  • Interferon-gamma / pharmacology*
  • Irinotecan
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Recombinant Proteins / pharmacology
  • Transplantation, Heterologous
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Interferon-alpha
  • Recombinant Proteins
  • Irinotecan
  • Interferon-beta
  • Interferon-gamma
  • Camptothecin